Literature DB >> 25985939

Transarterial approaches to primary and secondary hepatic malignancies.

Ali Habib1, Kush Desai1, Ryan Hickey1, Bartley Thornburg1, Robert Lewandowski1, Riad Salem1.   

Abstract

Transarterial therapies in the setting of primary and secondary liver malignancies are becoming an essential part of the oncology landscape. Most patients with hepatic malignancies are not candidates for curative surgical intervention, thereby warranting exploration of alternative means of treatment that preserves quality of life while providing clinical benefit. Herein, the data for intra-arterial chemoinfusion, transarterial chemoembolization, drug-eluting beads, and radioembolization are discussed in the setting of malignancies within the liver; outcome data relating to survival, time-to-progression, time-to-recurrence, and adverse events are presented. Further data regarding different treatment paradigms for hepatocellular carcinoma, metastatic colorectal carcinoma, neuroendocrine tumours, and intrahepatic cholangiocarcinoma are also provided. In light of these and forthcoming data, transarterial therapies seem to offer a viable treatment pathway for select populations of patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25985939     DOI: 10.1038/nrclinonc.2015.78

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  117 in total

1.  Ultrasound-Guided Radiological Placement of Central Venous Port via the Subclavian Vein: A Retrospective Analysis of 500 Cases at a Single Institute.

Authors:  Notiaki Sakamoto; Yasuaki Arai; Yoshito Takeuchi; Mahahide Takahashi; Masakatsu Tsurusaki; Kazuro Sugimuta
Journal:  Cardiovasc Intervent Radiol       Date:  2010-10       Impact factor: 2.740

2.  Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein.

Authors:  J Fan; Z Q Wu; Z Y Tang; J Zhou; S J Qiu; Z C Ma; X D Zhou; S L Ye
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

3.  Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation.

Authors:  J M Llovet; X Mas; J J Aponte; J Fuster; M Navasa; E Christensen; J Rodés; J Bruix
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

4.  Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results.

Authors:  C Aliberti; M Tilli; G Benea; G Fiorentini
Journal:  Anticancer Res       Date:  2006 Sep-Oct       Impact factor: 2.480

5.  Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans.

Authors:  Hashem B El-Serag; Eric A Engels; Ola Landgren; Elizabeth Chiao; Louise Henderson; Harshinie C Amaratunge; Thomas P Giordano
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

6.  Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.

Authors:  Laura M Kulik; Brian I Carr; Mary F Mulcahy; Robert J Lewandowski; Bassel Atassi; Robert K Ryu; Kent T Sato; Al Benson; Albert A Nemcek; Vanessa L Gates; Michael Abecassis; Reed A Omary; Riad Salem
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

7.  Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience.

Authors:  Sanjay Gupta; James C Yao; Kamran Ahrar; Michael J Wallace; Frank A Morello; David C Madoff; Ravi Murthy; Marshall E Hicks; Jaffer A Ajani
Journal:  Cancer J       Date:  2003 Jul-Aug       Impact factor: 3.360

Review 8.  Yttrium-90 microspheres: radiation therapy for unresectable liver cancer.

Authors:  Riad Salem; Kenneth G Thurston; Brian I Carr; James E Goin; Jean-Francois H Geschwind
Journal:  J Vasc Interv Radiol       Date:  2002-09       Impact factor: 3.464

9.  Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial.

Authors:  N Kemeny; J Daly; B Reichman; N Geller; J Botet; P Oderman
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  13 in total

1.  Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors.

Authors:  Martha M Kirstein; Steffen Marquardt; Nils Jedicke; Silke Marhenke; Wolfgang Koppert; Michael P Manns; Frank Wacker; Arndt Vogel
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-20       Impact factor: 4.553

2.  Transarterial Delivery of a Biodegradable Single-Agent Theranostic Nanoprobe for Liver Tumor Imaging and Combinatorial Phototherapy.

Authors:  Olena R Taratula; Oleh Taratula; Xiangjun Han; Younes Jahangiri; Yuki Tomozawa; Masahiro Horikawa; Barry Uchida; Hassan A Albarqi; Canan Schumann; Shay Bracha; Tetiana Korzun; Khashayar Farsad
Journal:  J Vasc Interv Radiol       Date:  2019-06-13       Impact factor: 3.464

3.  A single nucleotide polymorphism CTSB rs12898 is associated with primary hepatic cancer in a Chinese population.

Authors:  Minghua Cui; Quanzhu Chen; Chaojun He; Nan Wang; Yong Yu; Ziyang Sun; Zhenhua Lin; Hesong Cui; Shengyu Jin; Jae Yong Park; Guang Jin; Shin Yup Lee; Qingsong Cui
Journal:  Int J Clin Exp Pathol       Date:  2019-08-01

Review 4.  Decision Making for Selection of Transarterial Locoregional Therapy of Metastatic Neuroendocrine Tumors.

Authors:  Ron C Gaba; Nasya Mendoza-Elias; Joseph D Morrison; Ali Kord Valeshabad; Andrew J Lipnik
Journal:  Semin Intervent Radiol       Date:  2017-06-01       Impact factor: 1.513

Review 5.  Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.

Authors:  Tim F Greten; Chunwei Walter Lai; Guangfu Li; Kevin F Staveley-O'Carroll
Journal:  Gastroenterology       Date:  2018-10-01       Impact factor: 22.682

Review 6.  Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma.

Authors:  Sebastian Mondaca; Hooman Yarmohammadi; Nancy E Kemeny
Journal:  Surg Oncol Clin N Am       Date:  2019-08-07       Impact factor: 3.495

7.  Hepatic arterial infusion of irinotecan and EmboCept® S results in high tumor concentration of SN-38 in a rat model of colorectal liver metastases.

Authors:  Anne Kauffels; Marie Kitzmüller; Andrea Gruber; Hannah Nowack; Hanibal Bohnenberger; Melanie Spitzner; Anja Kuthning; Thilo Sprenger; Martin Czejka; Michael Ghadimi; Jens Sperling
Journal:  Clin Exp Metastasis       Date:  2019-01-24       Impact factor: 5.150

Review 8.  Oncolysis without viruses - inducing systemic anticancer immune responses with local therapies.

Authors:  Oliver Kepp; Aurelien Marabelle; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2019-10-08       Impact factor: 66.675

9.  MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma.

Authors:  Xiyang Wei; Lei Zhao; Ruizhe Ren; Fubo Ji; Shuting Xue; Jianjuan Zhang; Zhaogang Liu; Zhao Ma; Xin W Wang; Linda Wong; Niya Liu; Jiong Shi; Xing Guo; Stephanie Roessler; Xin Zheng; Junfang Ji
Journal:  Hepatology       Date:  2020-11-07       Impact factor: 17.298

10.  Safety and initial efficacy of radiation segmentectomy for the treatment of hepatic metastases​.

Authors:  Craig Meiers; Amy Taylor; Brian Geller; Beau Toskich
Journal:  J Gastrointest Oncol       Date:  2018-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.